RE:RE:RE:Aside from share price ... smells right for some bolt-onsMrMugsy wrote: You are correct.
This is definitely what you'd define as a value trap.
Has always been like that.
Even the bolt-ons likely won't offer real value from a share price perspective.
But they eventually will happen and the value trap will continue.
It took 19 years to become a success the first time - filled with years you'd define as "value trap."
I wouldn't bet on when - but I'd expect to beat 19 years this time around.
the 60+ people who control 70% of the business don't care about the trading price - most are not selling anyway. They're building a pharma and making sure no one gets in the way.
Eventually - this gets the attention of serious interest and additional accumulators.
Eventually there's demand for these shares.
But, I think the main business still has a lot of maturing to do.
Long way to go.
Don't hold me to it - just what I've always believed.
This thing moves sideway until it doesn't anymore ... that's exactly how it's designed - fully controlled by a few owners.
We have to be realistic too. If they can't growth + 15 % this year and have $ 45-50 M EBITDA many investors will be disapointed by the exucution/platform.
Yea + 15 % revenue growth and $ 45-50 M EBITDA are my expections for 2023. What are yours numbers expectations ?